Table 3.

Subgroup analysis for the accuracy of THSD7A‐AB for IMN detection

Subgroup	N	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio	AUC
Method
Western blotting	6	0.04 (0.03–0.06)	0.99 (0.98–1.00)	7.60 (1.70–34.20)	0.97 (0.95–0.98)	0.72 (0.68–0.76)
IFT	3	–	–	–	–	–
ELISA	5	0.06 (0.02–0.19)	0.99 (0.91–1.00)	8.30 (1.00–71.10)	0.95 (0.89–1.02)	0.68 (0.64–0.72)
Region
Europe	5	0.03 (0.02–0.04)	1.00 (0.98–1.00)	10.20 (1.40–73.40)	0.97 (0.96–0.98)	0.83 (0.80–0.86)
America	1	–	–	–	–	–
Asia	8	0.04 (0.02–0.11)	0.99 (0.97–1.00)	3.60 (1.60–8.50)	0.97 (0.93–1.00)	0.83 (0.79–0.86)
Sample size
>200	7	0.03 (0.02–0.03)	0.99 (0.98–1.00)	4.90 (1.80–13.40)	0.98 (0.97–0.99)	0.99 (0.97–0.99)
≤200	7	0.06 (0.02–0.14)	0.99 (0.95–1.00)	5.50 (1.50–21.20)	0.95 (0.91–1.00)	0.76 (0.72–0.79)
Interval
No	8	0.04 (0.02–0.11)	0.99 (0.97–1.00)	3.60 (1.60–8.50)	0.97 (0.93–1.00)	0.83 (0.79–0.86)
After biopsy test	6	0.03 (0.02–0.04)	1.00 (0.98–1.00)	11.80 (1.60–85.00)	0.97 (0.96–0.98)	0.85 (0.81–0.87)
Control
SMN	6	0.03 (0.01–0.10)	0.98 (0.93–0.99)	1.50 (0.60–3.80)	0.99 (0.96–1.02)	0.65 (0.61–0.69)
Other glomerular disease	12	0.04 (0.02–0.08)	1.00 (0.98–1.00)	30.4 (2.70–339.20)	0.96 (0.94–0.98)	0.86 (0.83–0.89)
Health	3	–	–	–	–	–